Exciting progress in CB1 drug design! Two Gi-biased agonists, LZD503 and LZD505, show promise for reducing side effects, enhancing non-opioid therapy. PMID:41980782, Cell 2026, @Cell https://www.cell.com/cell/fulltext/S0092-8674(26)00287-4 #Medsky #Pharmsky #RNA #ASHG #ESHG 🧪
